<DOC>
	<DOCNO>NCT02276027</DOCNO>
	<brief_summary>To investigate anti-tumor activity single agent BYL719 , INC280 , LDK378 MEK162</brief_summary>
	<brief_title>A Phase II , Open Label , Multiple Arm Study AUY922 , BYL719 , INC280 , LDK378 MEK162 Chinese Patients With Advanced Non-small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Ceritinib</mesh_term>
	<criteria>Advanced ( stage IIIB stage IV ) NSCLC Must specific molecular alteration Symptomatic central nervous system ( CNS ) metastases neurologically unstable require increase dos steroid within 4 week prior study entry control CNS disease Radiation therapy within ≤ 4 week prior study entry , exception limit field palliative radiotherapy bone pain relief . Any malignancy within last 5 year study entry Major surgery ≤ 2 week prior study entry recover side effect therapy Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>adenocarcinoma lung cancer , squamous cell lung carcinoma , NSCLC</keyword>
</DOC>